Vault-13

Affinity Asset Advisors, LLC

NEW YORK, NY · CIK 1773195 · 13F filing filed 2026-08-13

SEC-registered investment adviser since 2021 · limited liability company

$2.0bn reported value +19.9% vs Q1 2026
104positions
42.6%in top 10
19 new 33 added 28 reduced 10 sold out vs Q1 2026

Options: 6 call positions ($112.6m notional), 3 put positions ($55.1m notional) – listed below, not included above.

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 ROIVANT SCIENCES LTD SHS ROIV ROIV 3,750,000 $132.7m6.49% 6.49% AddedShares held: Q3 2025 800.0k, Q4 2025 1.7m, Q1 2026 2.8m, Q2 2026 3.8m +950.0k +950,000 33.9%
2 APOGEE THERAPEUTICS INC COM COM 987,000 $131.0m6.41% 6.41% ReducedShares held: Q3 2025 1.2m, Q4 2025 1.2m, Q1 2026 1.3m, Q2 2026 987.0k -297.9k -297,926 -23.2%
3 SPYRE THERAPEUTICS INC COM NEW SYRE SYRE 1,279,134 $113.6m5.55% 5.55% UnchangedShares held: Q3 2025 1.4m, Q4 2025 1.4m, Q1 2026 1.3m, Q2 2026 1.3m
4 XENON PHARMACEUTICALS INC COM XENE XENE 1,595,000 $96.3m4.71% 4.71% ReducedShares held: Q3 2025 1.4m, Q4 2025 1.2m, Q1 2026 1.7m, Q2 2026 1.6m -80.0k -80,000 -4.8%
5 ERASCA INC COM ERAS ERAS 5,250,000 $96.2m4.70% 4.70% ReducedShares held: Q3 2025 4.3m, Q4 2025 3.9m, Q1 2026 5.3m, Q2 2026 5.2m -100.0k -100,000 -1.9%
6 INSMED INC COM PAR $.01 INSM INSM 650,000 $69.3m3.39% 3.39% AddedShares held: Q3 2025 450.0k, Q4 2025 450.0k, Q1 2026 480.0k, Q2 2026 650.0k +170.0k +170,000 35.4%
7 PRAXIS PRECISION MEDICINES I COM NEW PRAX PRAX 185,000 $61.9m3.03% 3.03% AddedShares held: Q3 2025 0, Q4 2025 185.0k, Q1 2026 170.0k, Q2 2026 185.0k +15.0k +15,000 8.8%
8 ALKERMES PLC SHS ALKS ALKS 1,125,000 $58.9m2.88% 2.88% ReducedShares held: Q3 2025 1.2m, Q4 2025 1.0m, Q1 2026 1.4m, Q2 2026 1.1m -225.0k -225,000 -16.7%
9 ORUKA THERAPEUTICS INC COM ORKA ORKA 590,000 $56.2m2.75% 2.75% AddedShares held: Q3 2025 959.2k, Q4 2025 802.3k, Q1 2026 499.7k, Q2 2026 590.0k +90.3k +90,327 18.1%
10 ANAPTYSBIO INC COM ANAB ANAB 826,109 $55.8m2.73% 2.73% ReducedShares held: Q3 2025 0, Q4 2025 444.7k, Q1 2026 940.0k, Q2 2026 826.1k -113.9k -113,891 -12.1%
11 AVALO THERAPEUTICS INC COM NEW AVTX AVTX 2,900,000 $53.6m2.62% 2.62% AddedShares held: Q3 2025 1.0m, Q4 2025 1.1m, Q1 2026 1.3m, Q2 2026 2.9m +1.6m +1,559,160 116.3%
12 CYTOKINETICS INC COM NEW CYTK CYTK 550,000 $46.9m2.29% 2.29% ReducedShares held: Q3 2025 350.0k, Q4 2025 800.0k, Q1 2026 700.5k, Q2 2026 550.0k -150.5k -150,483 -21.5%
13 REVOLUTION MEDICINES INC COM RVMD RVMD 250,000 $46.8m2.29% 2.29% AddedShares held: Q3 2025 100.0k, Q4 2025 100.0k, Q1 2026 100.0k, Q2 2026 250.0k +150.0k +150,000 150.0%
14 ABIVAX SA SPONSORED ADS ABVX ABVX 330,000 $44.0m2.15% 2.15% ReducedShares held: Q3 2025 360.0k, Q4 2025 505.0k, Q1 2026 405.0k, Q2 2026 330.0k -75.0k -75,000 -18.5%
15 FIRST TRACKS BIOTHERAPEUTICS ORD SHS TRAX TRAX 2,032,012 $40.9m2.00% 2.00% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 2.0m
16 DIANTHUS THERAPEUTICS INC COM DNTH DNTH 400,000 $39.0m1.91% 1.91% AddedShares held: Q3 2025 262.1k, Q4 2025 115.0k, Q1 2026 350.0k, Q2 2026 400.0k +50.0k +50,000 14.3%
17 SUTRO BIOPHARMA INC COM SHS STRO STRO 1,172,487 $38.9m1.90% 1.90% AddedShares held: Q3 2025 0, Q4 2025 748.4k, Q1 2026 1.1m, Q2 2026 1.2m +103.0k +102,968 9.6%
18 NUVALENT INC COM COM 275,000 $34.0m1.66% 1.66% ReducedShares held: Q3 2025 384.4k, Q4 2025 322.6k, Q1 2026 300.0k, Q2 2026 275.0k -25.0k -25,000 -8.3%
19 TREVI THERAPEUTICS INC COM TRVI TRVI 1,800,172 $33.6m1.64% 1.64% ReducedShares held: Q3 2025 2.8m, Q4 2025 2.2m, Q1 2026 2.0m, Q2 2026 1.8m -200.0k -200,000 -10.0%
20 OVID THERAPEUTICS INC COM OVID OVID 10,144,562 $27.3m1.33% 1.33% ReducedShares held: Q3 2025 2.6m, Q4 2025 7.2m, Q1 2026 10.6m, Q2 2026 10.1m -491.8k -491,756 -4.6%
21 LEXEO THERAPEUTICS INC COM LXEO LXEO 5,807,611 $27.0m1.32% 1.32% AddedShares held: Q3 2025 3.9m, Q4 2025 3.2m, Q1 2026 5.1m, Q2 2026 5.8m +757.4k +757,400 15.0%
22 CELLDEX THERAPEUTICS INC NEW COM NEW CLDX CLDX 700,000 $26.0m1.27% 1.27% AddedShares held: Q3 2025 300.0k, Q4 2025 350.0k, Q1 2026 500.0k, Q2 2026 700.0k +200.0k +200,000 40.0%
23 BELITE BIO INC SPONSORED ADS BLTE BLTE 165,000 $25.4m1.24% 1.24% AddedShares held: Q3 2025 0, Q4 2025 20.0k, Q1 2026 65.0k, Q2 2026 165.0k +100.0k +100,000 153.8%
24 ENLIVEN THERAPEUTICS INC COM ELVN ELVN 500,000 $25.4m1.24% 1.24% ReducedShares held: Q3 2025 400.0k, Q4 2025 0, Q1 2026 586.9k, Q2 2026 500.0k -86.9k -86,904 -14.8%
25 FORTE BIOSCIENCES INC COM NEW FBRX FBRX 1,145,391 $24.3m1.19% 1.19% AddedShares held: Q3 2025 0, Q4 2025 989.5k, Q1 2026 1.0m, Q2 2026 1.1m +133.5k +133,501 13.2%
26 NURIX THERAPEUTICS INC COM NRIX NRIX 967,620 $23.5m1.15% 1.15% UnchangedShares held: Q3 2025 967.6k, Q4 2025 967.6k, Q1 2026 967.6k, Q2 2026 967.6k
27 ALTO NEUROSCIENCE INC COM SHS ANRO ANRO 850,000 $22.4m1.10% 1.10% AddedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 500.0k, Q2 2026 850.0k +350.0k +350,000 70.0%
28 MADRIGAL PHARMACEUTICALS INC COM MDGL MDGL 40,000 $21.5m1.05% 1.05% ReducedShares held: Q3 2025 115.0k, Q4 2025 31.1k, Q1 2026 55.0k, Q2 2026 40.0k -15.0k -15,000 -27.3%
29 PROTAGONIST THERAPEUTICS INC COM PTGX PTGX 172,125 $21.1m1.03% 1.03% UnchangedShares held: Q3 2025 220.6k, Q4 2025 172.1k, Q1 2026 172.1k, Q2 2026 172.1k
30 MINERALYS THERAPEUTICS INC COM MLYS MLYS 750,000 $20.2m0.99% 0.99% UnchangedShares held: Q3 2025 750.0k, Q4 2025 730.0k, Q1 2026 750.0k, Q2 2026 750.0k
31 RELAY THERAPEUTICS INC COM RLAY RLAY 1,050,000 $19.6m0.96% 0.96% AddedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 400.0k, Q2 2026 1.1m +650.0k +650,000 162.5%
32 SAGIMET BIOSCIENCES INC COM SER A SGMT SGMT 2,497,864 $19.3m0.94% 0.94% AddedShares held: Q3 2025 350.0k, Q4 2025 1.1m, Q1 2026 868.0k, Q2 2026 2.5m +1.6m +1,629,844 187.8%
33 JADE BIOSCIENCES INC COM NEW JBIO JBIO 840,350 $18.7m0.91% 0.91% AddedShares held: Q3 2025 65.3k, Q4 2025 715.0k, Q1 2026 640.0k, Q2 2026 840.4k +200.4k +200,394 31.3%
34 COGENT BIOSCIENCES INC COM COGT COGT 450,000 $17.4m0.85% 0.85% ReducedShares held: Q3 2025 0, Q4 2025 350.0k, Q1 2026 750.0k, Q2 2026 450.0k -300.0k -300,000 -40.0%
35 TRAVERE THERAPEUTICS INC COM TVTX TVTX 300,000 $17.0m0.83% 0.83% UnchangedShares held: Q3 2025 500.0k, Q4 2025 300.0k, Q1 2026 300.0k, Q2 2026 300.0k
36 CULLINAN THERAPEUTICS INC COM CGEM CGEM 875,760 $15.9m0.78% 0.78% AddedShares held: Q3 2025 263.8k, Q4 2025 1.9m, Q1 2026 781.3k, Q2 2026 875.8k +94.5k +94,500 12.1%
37 SAVARA INC COM SVRA SVRA 2,512,153 $15.5m0.76% 0.76% UnchangedShares held: Q3 2025 1.5m, Q4 2025 2.8m, Q1 2026 2.5m, Q2 2026 2.5m
38 IDEAYA BIOSCIENCES INC COM IDYA IDYA 400,000 $14.9m0.73% 0.73% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 400.0k
39 PERSPECTIVE THERAPEUTICS INC COM NEW CATX CATX 4,214,582 $14.4m0.70% 0.70% AddedShares held: Q3 2025 300.0k, Q4 2025 300.0k, Q1 2026 3.2m, Q2 2026 4.2m +1.1m +1,050,000 33.2%
40 ODYSSEY THERAPEUTICS INC COMMON STOCK ODTX ODTX 766,346 $14.3m0.70% 0.70% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 766.3k
41 COGENT BIOSCIENCES INC NOTE 1.625%11/1 · principal COGT 1.625 11.15.31 · principal COGT 1.625 11.15.31 11,000,000 $13.7m0.67% 0.67% AddedPrincipal held: Q3 2025 0, Q4 2025 1.0m, Q1 2026 7.0m, Q2 2026 11.0m +4.0m +4,000,000 57.1%
42 HELIX ACQUISITION CORP III USD CL A ORD SHS HLXC HLXC 1,250,000 $13.3m0.65% 0.65% UnchangedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 1.2m, Q2 2026 1.2m
43 EQUILLIUM INC COM EQ EQ 4,100,000 $13.1m0.64% 0.64% AddedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 1.2m, Q2 2026 4.1m +2.9m +2,873,690 234.3%
44 ESTABLISHMENT LABS HLDGS INC COM ESTA ESTA 148,013 $12.7m0.62% 0.62% AddedShares held: Q3 2025 310.0k, Q4 2025 200.0k, Q1 2026 100.0k, Q2 2026 148.0k +48.0k +48,013 48.0%
45 CLIMB BIO INC COM CLYM CLYM 972,000 $12.7m0.62% 0.62% AddedShares held: Q3 2025 1.3m, Q4 2025 1.3m, Q1 2026 700.0k, Q2 2026 972.0k +272.0k +272,000 38.9%
46 TEVA PHARMACEUTICAL INDS LTD SPONSORED ADS SPONSORED ADS 374,000 $12.7m0.62% 0.62% ReducedShares held: Q3 2025 1.4m, Q4 2025 1.4m, Q1 2026 1.4m, Q2 2026 374.0k -1.0m -1,026,000 -73.3%
47 VERADERMICS INC COMMON STOCK MANE MANE 100,000 $12.3m0.60% 0.60% AddedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 70.0k, Q2 2026 100.0k +30.0k +30,000 42.9%
48 ARROWHEAD PHARMACEUTICALS IN COM ARWR ARWR 150,000 $12.2m0.60% 0.60% ReducedShares held: Q3 2025 0, Q4 2025 70.0k, Q1 2026 200.0k, Q2 2026 150.0k -50.0k -50,000 -25.0%
49 OMEROS CORP NOTE 9.500% 6/1 · principal OMER 9.5 06.15.29 · principal OMER 9.5 06.15.29 6,525,000 $12.2m0.60% 0.60% UnchangedPrincipal held: Q3 2025 5.5m, Q4 2025 6.5m, Q1 2026 6.5m, Q2 2026 6.5m
50 TAYSHA GENE THERAPIES INC COM SHS TSHA TSHA 1,750,000 $11.9m0.58% 0.58% AddedShares held: Q3 2025 3.0m, Q4 2025 3.3m, Q1 2026 1.0m, Q2 2026 1.8m +750.0k +750,000 75.0%
51 DAMORA THERAPEUTICS INC COM NEW COM NEW 425,000 $11.1m0.54% 0.54% ReducedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 450.0k, Q2 2026 425.0k -25.0k -25,000 -5.6%
52 EUPRAXIA PHARMACEUTICALS INC COM EPRX EPRX 1,650,000 $10.9m0.53% 0.53% AddedShares held: Q3 2025 300.0k, Q4 2025 300.0k, Q1 2026 1.6m, Q2 2026 1.6m +61.0k +60,995 3.8%
53 VERA THERAPEUTICS INC CL A VERA VERA 250,000 $10.7m0.52% 0.52% UnchangedShares held: Q3 2025 303.3k, Q4 2025 250.0k, Q1 2026 250.0k, Q2 2026 250.0k
54 PROQR THRAPEUTICS N V SHS EURO PRQR PRQR 5,543,936 $10.3m0.50% 0.50% AddedShares held: Q3 2025 3.6m, Q4 2025 2.5m, Q1 2026 2.5m, Q2 2026 5.5m +3.1m +3,089,658 125.9%
55 NEWAMSTERDAM PHARMA COMPANY ORDINARY SHARES NAMS NAMS 275,000 $9.3m0.46% 0.46% UnchangedShares held: Q3 2025 275.0k, Q4 2025 275.0k, Q1 2026 275.0k, Q2 2026 275.0k
56 KORRO BIO INC COM KRRO KRRO 706,904 $9.3m0.46% 0.46% UnchangedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 706.9k, Q2 2026 706.9k
57 ANTERIS TECHNOLOGIES GLOBAL COM AVR AVR 912,397 $9.0m0.44% 0.44% UnchangedShares held: Q3 2025 450.0k, Q4 2025 486.7k, Q1 2026 912.4k, Q2 2026 912.4k
58 ZURA BIO LTD CLASS A ORD SHS ZURA ZURA 1,464,303 $8.6m0.42% 0.42% ReducedShares held: Q3 2025 1.3m, Q4 2025 1.8m, Q1 2026 2.6m, Q2 2026 1.5m -1.1m -1,100,000 -42.9%
59 UNIQURE NV SHS QURE QURE 175,000 $8.1m0.39% 0.39% NewShares held: Q3 2025 300.0k, Q4 2025 50.0k, Q1 2026 0, Q2 2026 175.0k
60 ASCENDIS PHARMA A/S ORD SHS ASND ASND 30,000 $8.0m0.39% 0.39% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 30.0k
61 IBIO INC COM NEW IBIO IBIO 4,007,881 $7.0m0.34% 0.34% AddedShares held: Q3 2025 0, Q4 2025 2.1m, Q1 2026 3.1m, Q2 2026 4.0m +900.7k +900,681 29.0%
62 GENERATE BIOMEDICINES INC COM SHS GENB GENB 400,000 $6.7m0.33% 0.33% AddedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 350.0k, Q2 2026 400.0k +50.0k +50,000 14.3%
63 TYRA BIOSCIENCES INC COM TYRA TYRA 200,012 $6.4m0.31% 0.31% ReducedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 257.5k, Q2 2026 200.0k -57.5k -57,500 -22.3%
64 SOL-GEL TECHNOLOGIES LTD SHS NEW SLGL SLGL 84,900 $6.3m0.31% 0.31% AddedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 35.0k, Q2 2026 84.9k +49.9k +49,900 142.6%
65 SAB BIOTHERAPEUTICS INC COM NEW SABS SABS 1,525,000 $5.9m0.29% 0.29% AddedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 575.0k, Q2 2026 1.5m +950.0k +950,000 165.2%
66 MACROGENICS INC COM MGNX MGNX 1,216,606 $5.6m0.27% 0.27% AddedShares held: Q3 2025 0, Q4 2025 484.3k, Q1 2026 500.0k, Q2 2026 1.2m +716.6k +716,606 143.3%
67 CRISPR THERAPEUTICS AG NAMEN AKT CRSP CRSP 100,000 $5.5m0.27% 0.27% ReducedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 150.0k, Q2 2026 100.0k -50.0k -50,000 -33.3%
68 NEWAMSTERDAM PHARMA COMPANY *W EXP 11/22/202 NAMSW NAMSW 245,000 $5.3m0.26% 0.26% UnchangedShares held: Q3 2025 245.0k, Q4 2025 245.0k, Q1 2026 245.0k, Q2 2026 245.0k
69 ASSEMBLY BIOSCIENCES INC COM NEW ASMB ASMB 190,000 $5.2m0.26% 0.26% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 190.0k
70 REZOLUTE INC COM NEW RZLT RZLT 1,000,000 $5.2m0.25% 0.25% ReducedShares held: Q3 2025 2.1m, Q4 2025 2.4m, Q1 2026 1.5m, Q2 2026 1.0m -547.6k -547,641 -35.4%
71 PRECISION BIOSCIENCES INC COM NEW DTIL DTIL 646,576 $5.1m0.25% 0.25% AddedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 597.9k, Q2 2026 646.6k +48.6k +48,630 8.1%
72 HEMAB THERAPEUTICS HLDGS INC COM SHS COAG COAG 138,030 $5.1m0.25% 0.25% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 138.0k
73 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 250,000 $4.6m0.22% 0.22% UnchangedShares held: Q3 2025 250.0k, Q4 2025 250.0k, Q1 2026 250.0k, Q2 2026 250.0k
74 ARRIVENT BIOPHARMA INC COM AVBP AVBP 125,000 $4.3m0.21% 0.21% ReducedShares held: Q3 2025 0, Q4 2025 150.0k, Q1 2026 175.0k, Q2 2026 125.0k -50.0k -50,000 -28.6%
75 VERRICA PHARMACEUTICALS INC COM SHS VRCA VRCA 707,338 $4.3m0.21% 0.21% UnchangedShares held: Q3 2025 0, Q4 2025 707.3k, Q1 2026 707.3k, Q2 2026 707.3k
76 COMPASS PATHWAYS PLC SPONSORED ADS CMPS CMPS 301,183 $4.3m0.21% 0.21% ReducedShares held: Q3 2025 200.0k, Q4 2025 200.0k, Q1 2026 1.1m, Q2 2026 301.2k -807.3k -807,300 -72.8%
77 MBX BIOSCIENCES INC COM MBX MBX 75,000 $4.1m0.20% 0.20% ReducedShares held: Q3 2025 165.0k, Q4 2025 250.0k, Q1 2026 150.0k, Q2 2026 75.0k -75.0k -75,000 -50.0%
78 RESEARCH ALLIANCE CORP III ORD SHS CL A RACC RACC 370,000 $4.0m0.19% 0.19% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 370.0k
79 IMMUNOVANT INC COM IMVT IMVT 100,000 $3.9m0.19% 0.19% UnchangedShares held: Q3 2025 300.0k, Q4 2025 200.0k, Q1 2026 100.0k, Q2 2026 100.0k
80 AMANAT ACQUISITION CORP CL A ORD AMAN AMAN 375,000 $3.8m0.19% 0.19% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 375.0k
81 BIOHAVEN LTD COM BHVN BHVN 250,000 $3.7m0.18% 0.18% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 250.0k
82 FAETH THERAPEUTICS INC COM NEW FTH FTH 144,404 $3.6m0.18% 0.18% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 144.4k
83 KARYOPHARM THERAPEUTICS INC COM NEW KPTI KPTI 312,500 $3.1m0.15% 0.15% ReducedShares held: Q3 2025 0, Q4 2025 889.6k, Q1 2026 500.0k, Q2 2026 312.5k -187.5k -187,500 -37.5%
84 ALECTOR INC COM ALEC ALEC 1,510,000 $3.0m0.15% 0.15% AddedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 500.0k, Q2 2026 1.5m +1.0m +1,010,000 202.0%
85 SPYGLASS PHARMA INC COM SHS SGP SGP 131,586 $2.9m0.14% 0.14% ReducedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 250.0k, Q2 2026 131.6k -118.4k -118,414 -47.4%
86 CRINETICS PHARMACEUTICALS IN COM CRNX CRNX 75,000 $2.8m0.14% 0.14% UnchangedShares held: Q3 2025 75.0k, Q4 2025 75.0k, Q1 2026 75.0k, Q2 2026 75.0k
87 OAKTREE ACQUISITION CORP III UNIT 10/04/2029 OACCU OACCU 250,000 $2.8m0.13% 0.13% UnchangedShares held: Q3 2025 250.0k, Q4 2025 250.0k, Q1 2026 250.0k, Q2 2026 250.0k
88 CELCUITY INC NOTE 0.250% 8/0 · principal CELC 0.25 08.01.32 · principal CELC 0.25 08.01.32 2,000,000 $2.3m0.11% 0.11% NewPrincipal held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 2.0m
89 JATT II ACQUISITION CORP ORD SHS JATT JATT 200,000 $2.3m0.11% 0.11% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 200.0k
90 NEUMORA THERAPEUTICS INC. COM NMRA NMRA 1,070,651 $1.8m0.09% 0.09% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 1.1m
91 AMYLYX PHARMACEUTICALS INC COM AMLX AMLX 98,999 $1.8m0.09% 0.09% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 99.0k
92 ADLAI NORTYE LTD SPONSORED ADS ANL ANL 153,847 $1.8m0.09% 0.09% ReducedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 164.7k, Q2 2026 153.8k -10.9k -10,901 -6.6%
93 SPRUCE BIOSCIENCES INC COM NEW SPRB SPRB 30,000 $1.6m0.08% 0.08% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 30.0k
94 EIKON THERAPEUTICS INC COM EIKN EIKN 98,001 $1.3m0.06% 0.06% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 98.0k
95 ONKURE THERAPEUTICS INC COM CL A OKUR OKUR 240,963 $1.1m0.05% 0.05% UnchangedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 241.0k, Q2 2026 241.0k
96 ENGENE THERAPEUTICS INC COM ENGN ENGN 600,000 $1.0m0.05% 0.05% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 600.0k
97 X4 PHARMACEUTICALS INC COM NEW XFOR XFOR 145,000 $677.1k0.03% 0.03% UnchangedShares held: Q3 2025 0, Q4 2025 145.0k, Q1 2026 145.0k, Q2 2026 145.0k
98 BOUNDLESS BIO INC COM BOLD BOLD 250,000 $625.0k0.03% 0.03% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 250.0k
99 LENZ THERAPEUTICS INC COM LENZ LENZ 100,000 $568.0k0.03% 0.03% UnchangedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 100.0k, Q2 2026 100.0k
100 Q32 BIO INC COM QTTB QTTB 27,777 $353.9k0.02% 0.02% UnchangedShares held: Q3 2025 27.8k, Q4 2025 27.8k, Q1 2026 27.8k, Q2 2026 27.8k

Sold out since Q1 2026

SecurityTickerShares held beforeValue then
CENTESSA PHARMACEUTICALS PLC 1,400,000 $55.6m1.4m shares
ARCELLX INC ACLX ACLX 362,764 $41.7m362.8k shares
TERNS PHARMACEUTICALS INC 562,631 $29.7m562.6k shares
ASCENDIS PHARMA A/S 95,000 $21.7m95.0k shares
BRIDGEBIO PHARMA INC BBIO BBIO 150,000 $11.1m150.0k shares
WAVE LIFE SCIENCES LTD 96663EUR 96663EUR 1,401,727 $10.2m1.4m shares
CELCUITY INC CELC 2.75 08.01.31 CELC 2.75 08.01.31 3,000,000 $7.3m3.0m shares
ENGENE HOLDINGS INC 610,370 $4.2m610.4k shares
CORCEPT THERAPEUTICS INC CORT CORT 50,000 $2.0m50.0k shares
KEZAR LIFE SCIENCES INC KZR KZR 229,076 $1.7m229.1k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
MODERNA INC MRNA · Put MRNAPut 500,000 $35.0m500.0k shares New
MODERNA INC MRNA · Call MRNACall 475,000 $33.3m475.0k shares Reduced
ARK ETF TR ARKG · Call ARKGCall 750,000 $31.5m750.0k shares New
ELI LILLY & CO LLY · Call LLYCall 20,000 $24.0m20.0k shares New
OMEROS CORP OMER · Put OMERPut 1,411,300 $13.4m1.4m shares New
ALKERMES PLC ALKS · Call ALKSCall 250,000 $13.1m250.0k shares New
UNIQURE NV QURE · Call QURECall 200,000 $9.2m200.0k shares Reduced
EVOMMUNE INC EVMN · Put EVMNPut 500,100 $6.6m500.1k shares New
SUMMIT THERAPEUTICS INC SMMT · Call SMMTCall 100,000 $1.5m100.0k shares New

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
IBIO INC IBIO · 13G · filed 2026-08-13 IBIO 10.0%≈ $8.9m no change 13G 2026-08-13
KARYOPHARM THERAPEUTICS INC KPTI · 13G · filed 2026-05-14 KPTI 8.6%≈ $20.3m no change 13G 2026-05-14
LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-13 LXEO 8.4%≈ $31.1m +1.3 pts 13G 2026-08-13
OVID THERAPEUTICS INC OVID · 13G · filed 2026-08-13 OVID 7.9%≈ $40.7m -1.2 pts 13G 2026-08-13
SUTRO BIOPHARMA INC 13G · filed 2025-10-23 7.8% new 13G 2025-10-23
HELIX ACQUISITION CORP III HLXC · 13G · filed 2026-05-14 HLXC 7.0%≈ $13.3m new 13G 2026-05-14
EQUILLIUM INC EQ · 13G · filed 2026-08-13 EQ 6.5%≈ $13.1m new 13G 2026-08-13
SUTRO BIOPHARMA INC STRO · 13G · filed 2026-05-14 STRO 6.5%≈ $35.5m -2.3 pts 13G 2026-05-14
NEXTCURE INC NXTC · 13G · filed 2026-08-13 NXTC 6.4%≈ $438.5k -3.6 pts 13G 2026-08-13
FIRST TRACKS BIOTHERAPEUTICS TRAX · 13G · filed 2026-08-13 TRAX 5.8%≈ $40.9m new 13G 2026-08-13
FORTE BIOSCIENCES INC FBRX · 13G · filed 2026-08-13 FBRX 5.6%≈ $24.3m -1.7 pts 13G 2026-08-13
AVALO THERAPEUTICS INC AVTX · 13G · filed 2026-08-13 AVTX 5.5%≈ $53.6m no change 13G 2026-08-13
VERRICA PHARMACEUTICALS INC VRCA · 13G · filed 2026-01-29 VRCA 5.5%≈ $5.4m no change 13G 2026-01-29
AMANAT ACQUISITION CORP AMAN · 13G · filed 2026-08-13 AMAN 5.0%≈ $3.8m new 13G 2026-08-13